TransMedics Group, Inc. (NASDAQ:TMDX) Holdings Lifted by Sandhill Capital Partners LLC

Sandhill Capital Partners LLC grew its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 4.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 763,201 shares of the company’s stock after buying an additional 30,591 shares during the period. TransMedics Group accounts for 5.0% of Sandhill Capital Partners LLC’s investment portfolio, making the stock its 3rd largest position. Sandhill Capital Partners LLC owned about 2.34% of TransMedics Group worth $60,239,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Atria Wealth Solutions Inc. purchased a new stake in TransMedics Group during the 4th quarter worth about $415,000. New York State Common Retirement Fund lifted its holdings in TransMedics Group by 41.9% during the 4th quarter. New York State Common Retirement Fund now owns 87,516 shares of the company’s stock worth $6,908,000 after purchasing an additional 25,849 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in TransMedics Group by 44.0% during the 4th quarter. Handelsbanken Fonder AB now owns 7,200 shares of the company’s stock worth $568,000 after purchasing an additional 2,200 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in TransMedics Group by 7.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,396 shares of the company’s stock worth $584,000 after purchasing an additional 483 shares in the last quarter. Finally, Mackenzie Financial Corp purchased a new stake in TransMedics Group during the 4th quarter worth about $35,804,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity

In related news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total transaction of $1,141,080.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,044,932.83. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Stephen Gordon sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $85.45, for a total transaction of $1,281,750.00. Following the transaction, the chief financial officer now directly owns 13,075 shares in the company, valued at approximately $1,117,258.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares of the company’s stock, valued at approximately $7,044,932.83. The disclosure for this sale can be found here. In the last three months, insiders have sold 117,078 shares of company stock worth $9,972,971. 6.70% of the stock is currently owned by insiders.

TransMedics Group Trading Up 0.4 %

Shares of TransMedics Group stock traded up $0.37 during trading on Thursday, hitting $89.25. 444,257 shares of the stock traded hands, compared to its average volume of 685,106. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The firm’s fifty day moving average is $82.94 and its 200-day moving average is $74.12. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $99.63.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Monday, February 26th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The company’s revenue was up 158.6% on a year-over-year basis. During the same period in the prior year, the company earned ($0.21) EPS. As a group, equities research analysts predict that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Piper Sandler assumed coverage on TransMedics Group in a report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price objective on the stock. Morgan Stanley raised their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Oppenheimer raised their price target on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a report on Tuesday, February 27th. Finally, JPMorgan Chase & Co. raised their price target on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $102.00.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.